Aadi bioscience to present new non-clinical data highlighting combinability of nab-sirolimus at the american association for cancer research (aacr) annual meeting

Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being investigated for patients with endometrioid-type endometrial cancer in a phase 2 trial data highlight potential for synergy to enhance anti-cancer effects and overcome resistance in non-small cell lung cancer los angeles , april 9, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mtor pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance. these data will be presented during poster sessions at the american association for cancer research (aacr) annual meeting in san diego, ca, taking place april 5-10, 2024.
AADI Ratings Summary
AADI Quant Ranking